Ursodeoxycholic Acid in Liver Diseases

Primary Biliary Cholangitis (PBC)

The American Association for the Study of Liver Diseases recommends UDCA at 13-15 mg/kg/day as the first-line treatment for PBC, which reduces mortality and need for liver transplantation 1, 2, 3
UDCA significantly decreases serum bilirubin, alkaline phosphatase, gamma-glutamyl transferase, cholesterol, and immunoglobulin M levels compared to placebo in patients with PBC 1, 2
Long-term UDCA treatment delays histological progression when started at early disease stages in patients with PBC 1, 2
UDCA reduces the likelihood of liver transplantation or death in patients with moderate to severe PBC 1, 2
Post-transplant UDCA at 10-15 mg/kg/day prevents disease recurrence in PBC patients 3
Biochemical response should be evaluated after 1 year of therapy to identify patients at risk of disease progression in PBC 1
UDCA does not significantly improve symptoms like fatigue or pruritus in PBC, despite improving biochemical markers 1

The American Association for the Study of Liver Diseases and British Society of Gastroenterology explicitly recommend against routine use of UDCA for PSC 1, 3
High-dose UDCA (28-30 mg/kg/day) is associated with worse outcomes including increased rates of liver transplantation, death, and variceal development in patients with PSC 1, 3
Moderate doses (15-20 mg/kg/day) may improve serum liver tests but do not improve clinical outcomes in patients with PSC 1

UDCA at 10-15 mg/kg/day divided into 2-3 doses is recommended for maternal pruritus relief in patients with ICP 1, 2
Pruritus typically improves within 1-2 weeks, with biochemical improvement in 3-4 weeks in patients with ICP 1
In ICP with serum bile acids >40 μmol/L, UDCA may reduce spontaneous preterm birth risk and potentially protect against stillbirth 2
UDCA is considered safe during pregnancy and breastfeeding 1

UDCA at 10-15 mg/kg/day is strongly recommended for patients with ABCB4 missense variants and clinical phenotype 3
In LPAC syndrome, UDCA at 8-10 mg/kg body weight achieves complete symptom resolution and normalization of liver tests 3
Transplant-free survival was 91% at median 14-year follow-up in ABCB4 deficiency patients receiving UDCA 3

UDCA is generally well tolerated, with mild nausea and dizziness occurring in up to 25% of patients 1
Regular monitoring of liver biochemistry (AST, ALT) is recommended at initiation and as clinically indicated in patients with PBC 1, 2

The American Association for the Study of Liver Diseases recommends regular monitoring of liver biochemistry, including AST and ALT, at treatment initiation and as clinically indicated, although UDCA therapy itself has not been associated with liver enzyme elevations and typically decreases enzyme levels 4, 5

The American Gastroenterological Association advises against using high-dose UDCA (>20 mg/kg/day) in any cholestatic condition, particularly primary sclerosing cholangitis, due to increased risk of adverse outcomes 4, 5
The European Association for the Study of the Liver recommends avoiding co-administration of UDCA with bile acid sequestrants, such as cholestyramine and colestipol, as they significantly impair UDCA absorption 4, 5
The National Institute of Diabetes and Digestive and Kidney Diseases notes that UDCA should not be administered to patients with end-stage cirrhosis or decompensated liver disease, as it may worsen liver function 4, 5